Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,542,749
  • Shares Outstanding, K 57,587
  • Annual Sales, $ 72,090 K
  • Annual Income, $ -581,780 K
  • 60-Month Beta 0.88
  • Price/Sales 73.09
  • Price/Cash Flow N/A
  • Price/Book 4.51
Trade MRTX with:

Options Overview Details

View History
  • Implied Volatility 167.66% ( -4.27%)
  • Historical Volatility 80.32%
  • IV Percentile 99%
  • IV Rank 96.68%
  • IV High 171.94% on 12/02/22
  • IV Low 43.23% on 01/06/22
  • Put/Call Vol Ratio 6.58
  • Today's Volume 728
  • Volume Avg (30-Day) 1,785
  • Put/Call OI Ratio 2.22
  • Today's Open Interest 44,645
  • Open Int (30-Day) 35,970

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -3.62
  • Number of Estimates 9
  • High Estimate -3.20
  • Low Estimate -5.06
  • Prior Year -3.72
  • Growth Rate Est. (year over year) +2.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.00 +63.84%
on 11/09/22
101.30 -9.43%
on 11/28/22
+28.61 (+45.31%)
since 11/04/22
3-Month
56.00 +63.84%
on 11/09/22
101.30 -9.43%
on 11/28/22
+10.72 (+13.23%)
since 09/02/22
52-Week
32.96 +178.37%
on 05/27/22
154.17 -40.49%
on 12/23/21
-40.60 (-30.68%)
since 12/03/21

Most Recent Stories

More News
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim...

MRTX : 90.74 (-5.72%)
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision...

BMY : 80.88 (-0.31%)
MRK : 109.55 (-0.45%)
AMGN : 285.71 (+0.07%)
MRTX : 90.74 (-5.72%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.9000 (+2.70%)
ONC.TO : 2.58 (+3.20%)
SGEN : 121.54 (-0.71%)
MRTX : 90.74 (-5.72%)
AMGN : 285.71 (+0.07%)
MACK : 11.88 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.9000 (+2.70%)
ONC.TO : 2.58 (+3.20%)
SGEN : 121.54 (-0.71%)
MRTX : 90.74 (-5.72%)
AMGN : 285.71 (+0.07%)
MACK : 11.88 (unch)
Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat

Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.

BMY : 80.88 (-0.31%)
MRK : 109.55 (-0.45%)
AVEO : 14.90 (-0.13%)
MRTX : 90.74 (-5.72%)
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 90.74 (-5.72%)
CDMO : 15.71 (-4.27%)
Mirati: Q3 Earnings Snapshot

Mirati: Q3 Earnings Snapshot

MRTX : 90.74 (-5.72%)
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...

MRTX : 90.74 (-5.72%)
Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to...

MRTX : 90.74 (-5.72%)
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination...

INCY : 84.16 (+1.24%)
MRTX : 90.74 (-5.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.

See More

Key Turning Points

3rd Resistance Point 107.72
2nd Resistance Point 102.15
1st Resistance Point 99.20
Last Price 90.74
1st Support Level 90.68
2nd Support Level 85.11
3rd Support Level 82.16

See More

52-Week High 154.17
Fibonacci 61.8% 107.87
Fibonacci 50% 93.57
Last Price 90.74
Fibonacci 38.2% 79.26
52-Week Low 32.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar